- Advanced search
- Immuno Portal
- Malaria Portal
Compound class: Antibody
Comment: Temelimab (GNbAC1) is a humanised IgG4κ monoclonal antibody that binds to the extracellular domain of the human endogenous retroviral envelope protein HERV-W-Env [3-5].
SARS-CoV-2: blocking HERV-W-Env has been proposed as a mechanism to target pathologic inflammation in COVID-19 patients, based on evidence of ERV-W-Env's immunopathogenic role in immune-mediated and neurological diseases and elevated HERV-W-Env expression in T cells from SARS-CoV-2 infected individuals .
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
|Positive signals of efficacy were detected in preclinical studies of temelimab (GNbAC1) in HERV-W-Env (MSRV-Env) induced experimental allergic encephalitis (EAE), an animal model of MS.|
|Selectivity at other protein targets|
|Key to terms and symbols||Click column headers to sort|